John C Reed sold $13M of JNJ
EVP, Innovative Medicine, R&D at JOHNSON & JOHNSON. 53,931 shares at an average of $243.00, traded Feb 17, 2026, filed Feb 18, 2026.
Score components
- +15RoleOfficer
- +25Trade size$13.1M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -3.4%, 3m -5.9%, 6m +12.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000200406-26-000039, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 15, 2026 | MOption exercise Common Stock | +1,349 | $0.00 | $0 | 12,007 | Feb 18, 2026 |
| Feb 15, 2026 | FTax withholding Common Stock | -385 | $243.45 | $94k | 11,622 | Feb 18, 2026 |
| Feb 15, 2026 | MOption exercise Common Stock | +1,847 | $0.00 | $0 | 13,469 | Feb 18, 2026 |
| Feb 15, 2026 | FTax withholding Common Stock | -528 | $243.45 | $129k | 12,941 | Feb 18, 2026 |
| Feb 17, 2026 | MOption exercise Common Stock | +21,721 | $157.92 | $3.4M | 34,662 | Feb 18, 2026 |
| Feb 17, 2026 | SOpen-market sale Common Stock | -21,721 | $243.00 | $5.3M | 12,941 | Feb 18, 2026 |
| Feb 17, 2026 | MOption exercise Common Stock | +29,927 | $156.15 | $4.7M | 42,868 | Feb 18, 2026 |
| Feb 17, 2026 | SOpen-market sale Common Stock | -29,927 | $243.00 | $7.3M | 12,941 | Feb 18, 2026 |
| Feb 17, 2026 | SOpen-market sale Common Stock | -2,283 | $243.00 | $555k | 10,658 | Feb 18, 2026 |
| Feb 15, 2026 | MOption exercise Restricted Share Unitsderivative | -1,349 | $0.00 | $0 | 1,349 | Feb 18, 2026 |
| Feb 15, 2026 | MOption exercise Restricted Share Unitsderivative | -1,847 | $0.00 | $0 | 3,692 | Feb 18, 2026 |
| Feb 15, 2026 | AGrant or award Employee Stock Options (Right to Buy)derivative | +49,382 | $0.00 | $0 | 49,382 | Feb 18, 2026 |
| Feb 15, 2026 | AGrant or award Restricted Share Unitsderivative | +3,546 | $0.00 | $0 | 3,546 | Feb 18, 2026 |
| Feb 17, 2026 | MOption exercise Employee Stock Options (Right to Buy)derivative | -21,721 | $0.00 | $0 | 21,721 | Feb 18, 2026 |
| Feb 17, 2026 | MOption exercise Employee Stock Options (Right to Buy)derivative | -29,927 | $0.00 | $0 | 59,854 | Feb 18, 2026 |
Related signals
Other insiders at JOHNSON & JOHNSON and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | JNJsell JOHNSON & JOHNSON | Timothy Schmid EVP, WW Chair, MedTech | $9.2M 33,597 shares | -92% | |
| 40Moderate | JOHNSON & JOHNSON | Jennifer L Taubert EVP, WWC. Innovative Medicine | $4.0M 15,000 shares | -7% | |
| 60Notable | JOHNSON & JOHNSON | Joaquin Duato CEO and Chairman of the Board | $32M 123,291 shares | -31% | |
| 70Notable | JOHNSON & JOHNSON | Joaquin Duato CEO and Chairman of the Board | $13M 48,480 shares | -15% | |
| 50Moderate | JOHNSON & JOHNSON | Elizabeth Forminard EVP, Chief Legal Officer | $4.1M 15,918 shares | -48% | |
| 45Moderate | JNJsell JOHNSON & JOHNSON | Vanessa Broadhurst EVP, Global Corp Affairs | $5.8M 23,054 shares | -50% | |
| 25Weak | JNJsell JOHNSON & JOHNSON | Kathryn E Wengel EVP, Chief TO and Risk Officer | $2.4M 10,000 shares | -8% | |
| 45Moderate | JOHNSON & JOHNSON | Robert J Decker VP Corporate Controller | $1.0M 4,075 shares | -15% | |
| 49Moderate | JOHNSON & JOHNSON | Timothy Schmid EVP, WW Chair, MedTech | $325k 1,322 shares | -5% | |
| 45Moderate | JOHNSON & JOHNSON | Vanessa Broadhurst EVP, Global Corp Affairs | $1.5M 6,197 shares | -21% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.